Increased urotensin-II activity in patients with Raynaud's phenomenon and systemic lupus erythematosus
Aim: Raynaud’s phenomenon (RP) commonly co‐exists with systemic lupus erythematosus (SLE). The obvious pathophysiological mechanism in RP is vasoconstriction. Although the roles of certain vasoconstrictor substances, like endothelin‐1, have been identified in RP, underlying mechanisms remain unclea...
Gespeichert in:
| Veröffentlicht in: | International journal of rheumatic diseases 2011-08, Vol.14 (3), p.276-281 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 281 |
|---|---|
| container_issue | 3 |
| container_start_page | 276 |
| container_title | International journal of rheumatic diseases |
| container_volume | 14 |
| creator | BUYUKHATIPOGLU, Hakan BUYUKASLAN, Hasan PEHLIVAN, Yavuz CEYLAN, Nurdan ULAS, Turgay TARAKCIOGLU, Mehmet ONAT, Ahmet M. |
| description | Aim: Raynaud’s phenomenon (RP) commonly co‐exists with systemic lupus erythematosus (SLE). The obvious pathophysiological mechanism in RP is vasoconstriction. Although the roles of certain vasoconstrictor substances, like endothelin‐1, have been identified in RP, underlying mechanisms remain unclear.
Methods: In this pilot study, we researched a relatively recently identified, very potent vasoconstrictor peptide, urotensin‐II (U‐II), in SLE patients versus those without RP. In addition to its vasoconstrictor effect, U‐II has been implicated in cardiovascular events and atherosclerosis. Increased frequencies of atherosclerosis and cardiovascular events comprise another issue in SLE patients. To address these effects, we included 15 Raynaud’s (+) and 15 Raynaud’s (−) SLE patients and compared both cohorts against age and sex‐matched controls.
Results: We found significantly elevated U‐II activity in both RP (+) and RP (−) SLE patients, relative to controls (P |
| doi_str_mv | 10.1111/j.1756-185X.2011.01597.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_881471262</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>881471262</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4117-d2fffa33bdf87a1a5f931934a09e35d0d9e42b59c1f38e7b178f501da7fa97c53</originalsourceid><addsrcrecordid>eNpdkcFu1DAQhi0EoqXwCsgSh54SPHFsJwcOVQvtSquCViB6s7yxrfWSOCG26ebtm7BlD1iyPNJ8_8iaDyEMJIf5fNznIBjPoGIPeUEAcgKsFvnhBTo_NV6e6hLO0JsQ9oRwoFy8RmcFVMBJUZ4ju_LNaFQwGqexj8YH57PVCqsmuj8uTth5PKjojI8BP7q4wxs1eZX0ZcDDzvi-m6_HymscphBN5xrcpiEFbMYp7kynYh9SeIteWdUG8-75vUA_vnz-fn2Xrb_erq6v1llTAohMF9ZaRelW20ooUMzWFGpaKlIbyjTRtSmLLasbsLQyYguisoyAVsKqWjSMXqDL49xh7H8nE6LsXGhM2ypv-hRkVUEpoODFTH74j9z3afTz5ySwsqwZ54zP1PtnKm07o-Uwuk6Nk_y3wBn4dAQeXWumUx-IXETJvVwcyMWHXETJv6LkQV59Wy_VnM-OeTcv73DKq_GX5IIKJn_e38qb-4dqIzZUrukTBsWXSw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1544956656</pqid></control><display><type>article</type><title>Increased urotensin-II activity in patients with Raynaud's phenomenon and systemic lupus erythematosus</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>BUYUKHATIPOGLU, Hakan ; BUYUKASLAN, Hasan ; PEHLIVAN, Yavuz ; CEYLAN, Nurdan ; ULAS, Turgay ; TARAKCIOGLU, Mehmet ; ONAT, Ahmet M.</creator><creatorcontrib>BUYUKHATIPOGLU, Hakan ; BUYUKASLAN, Hasan ; PEHLIVAN, Yavuz ; CEYLAN, Nurdan ; ULAS, Turgay ; TARAKCIOGLU, Mehmet ; ONAT, Ahmet M.</creatorcontrib><description>Aim: Raynaud’s phenomenon (RP) commonly co‐exists with systemic lupus erythematosus (SLE). The obvious pathophysiological mechanism in RP is vasoconstriction. Although the roles of certain vasoconstrictor substances, like endothelin‐1, have been identified in RP, underlying mechanisms remain unclear.
Methods: In this pilot study, we researched a relatively recently identified, very potent vasoconstrictor peptide, urotensin‐II (U‐II), in SLE patients versus those without RP. In addition to its vasoconstrictor effect, U‐II has been implicated in cardiovascular events and atherosclerosis. Increased frequencies of atherosclerosis and cardiovascular events comprise another issue in SLE patients. To address these effects, we included 15 Raynaud’s (+) and 15 Raynaud’s (−) SLE patients and compared both cohorts against age and sex‐matched controls.
Results: We found significantly elevated U‐II activity in both RP (+) and RP (−) SLE patients, relative to controls (P < 0.0001); however, the difference among RP (+) SLE patients was more prominent. U‐II was significantly elevated in RP (+) SLE patients when compared to RP (−) SLE patients (P < 0.001).
Conclusions: The results of our study suggest that, either as a cause or by‐product, U‐II may have some role in Raynaud’s‐related vasoconstriction. It also might contribute to atherosclerosis and cardiovascular diseases in SLE patients. Further studies clearly are warranted.</description><identifier>ISSN: 1756-1841</identifier><identifier>EISSN: 1756-185X</identifier><identifier>DOI: 10.1111/j.1756-185X.2011.01597.x</identifier><identifier>PMID: 21816024</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adult ; Atherosclerosis ; Autoimmune diseases ; Biomarkers - blood ; Comorbidity ; Female ; Humans ; Lupus ; Lupus Erythematosus, Systemic - blood ; Lupus Erythematosus, Systemic - epidemiology ; Lupus Erythematosus, Systemic - physiopathology ; Male ; Peptide Hormones - blood ; Pilot Projects ; Raynaud disease ; Raynaud Disease - blood ; Raynaud Disease - epidemiology ; Raynaud Disease - physiopathology ; Raynaud's phenomenon ; systemic lupus erythematosus ; Turkey - epidemiology ; urotensin-II</subject><ispartof>International journal of rheumatic diseases, 2011-08, Vol.14 (3), p.276-281</ispartof><rights>2011 The Authors. International Journal of Rheumatic Diseases © 2011 Asia Pacific League of Associations for Rheumatology and Blackwell Publishing Asia Pty Ltd</rights><rights>2011 The Authors. International Journal of Rheumatic Diseases © 2011 Asia Pacific League of Associations for Rheumatology and Blackwell Publishing Asia Pty Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4117-d2fffa33bdf87a1a5f931934a09e35d0d9e42b59c1f38e7b178f501da7fa97c53</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1756-185X.2011.01597.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1756-185X.2011.01597.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21816024$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BUYUKHATIPOGLU, Hakan</creatorcontrib><creatorcontrib>BUYUKASLAN, Hasan</creatorcontrib><creatorcontrib>PEHLIVAN, Yavuz</creatorcontrib><creatorcontrib>CEYLAN, Nurdan</creatorcontrib><creatorcontrib>ULAS, Turgay</creatorcontrib><creatorcontrib>TARAKCIOGLU, Mehmet</creatorcontrib><creatorcontrib>ONAT, Ahmet M.</creatorcontrib><title>Increased urotensin-II activity in patients with Raynaud's phenomenon and systemic lupus erythematosus</title><title>International journal of rheumatic diseases</title><addtitle>Int J Rheum Dis</addtitle><description>Aim: Raynaud’s phenomenon (RP) commonly co‐exists with systemic lupus erythematosus (SLE). The obvious pathophysiological mechanism in RP is vasoconstriction. Although the roles of certain vasoconstrictor substances, like endothelin‐1, have been identified in RP, underlying mechanisms remain unclear.
Methods: In this pilot study, we researched a relatively recently identified, very potent vasoconstrictor peptide, urotensin‐II (U‐II), in SLE patients versus those without RP. In addition to its vasoconstrictor effect, U‐II has been implicated in cardiovascular events and atherosclerosis. Increased frequencies of atherosclerosis and cardiovascular events comprise another issue in SLE patients. To address these effects, we included 15 Raynaud’s (+) and 15 Raynaud’s (−) SLE patients and compared both cohorts against age and sex‐matched controls.
Results: We found significantly elevated U‐II activity in both RP (+) and RP (−) SLE patients, relative to controls (P < 0.0001); however, the difference among RP (+) SLE patients was more prominent. U‐II was significantly elevated in RP (+) SLE patients when compared to RP (−) SLE patients (P < 0.001).
Conclusions: The results of our study suggest that, either as a cause or by‐product, U‐II may have some role in Raynaud’s‐related vasoconstriction. It also might contribute to atherosclerosis and cardiovascular diseases in SLE patients. Further studies clearly are warranted.</description><subject>Adult</subject><subject>Atherosclerosis</subject><subject>Autoimmune diseases</subject><subject>Biomarkers - blood</subject><subject>Comorbidity</subject><subject>Female</subject><subject>Humans</subject><subject>Lupus</subject><subject>Lupus Erythematosus, Systemic - blood</subject><subject>Lupus Erythematosus, Systemic - epidemiology</subject><subject>Lupus Erythematosus, Systemic - physiopathology</subject><subject>Male</subject><subject>Peptide Hormones - blood</subject><subject>Pilot Projects</subject><subject>Raynaud disease</subject><subject>Raynaud Disease - blood</subject><subject>Raynaud Disease - epidemiology</subject><subject>Raynaud Disease - physiopathology</subject><subject>Raynaud's phenomenon</subject><subject>systemic lupus erythematosus</subject><subject>Turkey - epidemiology</subject><subject>urotensin-II</subject><issn>1756-1841</issn><issn>1756-185X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkcFu1DAQhi0EoqXwCsgSh54SPHFsJwcOVQvtSquCViB6s7yxrfWSOCG26ebtm7BlD1iyPNJ8_8iaDyEMJIf5fNznIBjPoGIPeUEAcgKsFvnhBTo_NV6e6hLO0JsQ9oRwoFy8RmcFVMBJUZ4ju_LNaFQwGqexj8YH57PVCqsmuj8uTth5PKjojI8BP7q4wxs1eZX0ZcDDzvi-m6_HymscphBN5xrcpiEFbMYp7kynYh9SeIteWdUG8-75vUA_vnz-fn2Xrb_erq6v1llTAohMF9ZaRelW20ooUMzWFGpaKlIbyjTRtSmLLasbsLQyYguisoyAVsKqWjSMXqDL49xh7H8nE6LsXGhM2ypv-hRkVUEpoODFTH74j9z3afTz5ySwsqwZ54zP1PtnKm07o-Uwuk6Nk_y3wBn4dAQeXWumUx-IXETJvVwcyMWHXETJv6LkQV59Wy_VnM-OeTcv73DKq_GX5IIKJn_e38qb-4dqIzZUrukTBsWXSw</recordid><startdate>201108</startdate><enddate>201108</enddate><creator>BUYUKHATIPOGLU, Hakan</creator><creator>BUYUKASLAN, Hasan</creator><creator>PEHLIVAN, Yavuz</creator><creator>CEYLAN, Nurdan</creator><creator>ULAS, Turgay</creator><creator>TARAKCIOGLU, Mehmet</creator><creator>ONAT, Ahmet M.</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7QP</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>201108</creationdate><title>Increased urotensin-II activity in patients with Raynaud's phenomenon and systemic lupus erythematosus</title><author>BUYUKHATIPOGLU, Hakan ; BUYUKASLAN, Hasan ; PEHLIVAN, Yavuz ; CEYLAN, Nurdan ; ULAS, Turgay ; TARAKCIOGLU, Mehmet ; ONAT, Ahmet M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4117-d2fffa33bdf87a1a5f931934a09e35d0d9e42b59c1f38e7b178f501da7fa97c53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Atherosclerosis</topic><topic>Autoimmune diseases</topic><topic>Biomarkers - blood</topic><topic>Comorbidity</topic><topic>Female</topic><topic>Humans</topic><topic>Lupus</topic><topic>Lupus Erythematosus, Systemic - blood</topic><topic>Lupus Erythematosus, Systemic - epidemiology</topic><topic>Lupus Erythematosus, Systemic - physiopathology</topic><topic>Male</topic><topic>Peptide Hormones - blood</topic><topic>Pilot Projects</topic><topic>Raynaud disease</topic><topic>Raynaud Disease - blood</topic><topic>Raynaud Disease - epidemiology</topic><topic>Raynaud Disease - physiopathology</topic><topic>Raynaud's phenomenon</topic><topic>systemic lupus erythematosus</topic><topic>Turkey - epidemiology</topic><topic>urotensin-II</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BUYUKHATIPOGLU, Hakan</creatorcontrib><creatorcontrib>BUYUKASLAN, Hasan</creatorcontrib><creatorcontrib>PEHLIVAN, Yavuz</creatorcontrib><creatorcontrib>CEYLAN, Nurdan</creatorcontrib><creatorcontrib>ULAS, Turgay</creatorcontrib><creatorcontrib>TARAKCIOGLU, Mehmet</creatorcontrib><creatorcontrib>ONAT, Ahmet M.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BUYUKHATIPOGLU, Hakan</au><au>BUYUKASLAN, Hasan</au><au>PEHLIVAN, Yavuz</au><au>CEYLAN, Nurdan</au><au>ULAS, Turgay</au><au>TARAKCIOGLU, Mehmet</au><au>ONAT, Ahmet M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Increased urotensin-II activity in patients with Raynaud's phenomenon and systemic lupus erythematosus</atitle><jtitle>International journal of rheumatic diseases</jtitle><addtitle>Int J Rheum Dis</addtitle><date>2011-08</date><risdate>2011</risdate><volume>14</volume><issue>3</issue><spage>276</spage><epage>281</epage><pages>276-281</pages><issn>1756-1841</issn><eissn>1756-185X</eissn><abstract>Aim: Raynaud’s phenomenon (RP) commonly co‐exists with systemic lupus erythematosus (SLE). The obvious pathophysiological mechanism in RP is vasoconstriction. Although the roles of certain vasoconstrictor substances, like endothelin‐1, have been identified in RP, underlying mechanisms remain unclear.
Methods: In this pilot study, we researched a relatively recently identified, very potent vasoconstrictor peptide, urotensin‐II (U‐II), in SLE patients versus those without RP. In addition to its vasoconstrictor effect, U‐II has been implicated in cardiovascular events and atherosclerosis. Increased frequencies of atherosclerosis and cardiovascular events comprise another issue in SLE patients. To address these effects, we included 15 Raynaud’s (+) and 15 Raynaud’s (−) SLE patients and compared both cohorts against age and sex‐matched controls.
Results: We found significantly elevated U‐II activity in both RP (+) and RP (−) SLE patients, relative to controls (P < 0.0001); however, the difference among RP (+) SLE patients was more prominent. U‐II was significantly elevated in RP (+) SLE patients when compared to RP (−) SLE patients (P < 0.001).
Conclusions: The results of our study suggest that, either as a cause or by‐product, U‐II may have some role in Raynaud’s‐related vasoconstriction. It also might contribute to atherosclerosis and cardiovascular diseases in SLE patients. Further studies clearly are warranted.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>21816024</pmid><doi>10.1111/j.1756-185X.2011.01597.x</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1756-1841 |
| ispartof | International journal of rheumatic diseases, 2011-08, Vol.14 (3), p.276-281 |
| issn | 1756-1841 1756-185X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_881471262 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Atherosclerosis Autoimmune diseases Biomarkers - blood Comorbidity Female Humans Lupus Lupus Erythematosus, Systemic - blood Lupus Erythematosus, Systemic - epidemiology Lupus Erythematosus, Systemic - physiopathology Male Peptide Hormones - blood Pilot Projects Raynaud disease Raynaud Disease - blood Raynaud Disease - epidemiology Raynaud Disease - physiopathology Raynaud's phenomenon systemic lupus erythematosus Turkey - epidemiology urotensin-II |
| title | Increased urotensin-II activity in patients with Raynaud's phenomenon and systemic lupus erythematosus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T05%3A09%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Increased%20urotensin-II%20activity%20in%20patients%20with%20Raynaud's%20phenomenon%20and%20systemic%20lupus%20erythematosus&rft.jtitle=International%20journal%20of%20rheumatic%20diseases&rft.au=BUYUKHATIPOGLU,%20Hakan&rft.date=2011-08&rft.volume=14&rft.issue=3&rft.spage=276&rft.epage=281&rft.pages=276-281&rft.issn=1756-1841&rft.eissn=1756-185X&rft_id=info:doi/10.1111/j.1756-185X.2011.01597.x&rft_dat=%3Cproquest_pubme%3E881471262%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1544956656&rft_id=info:pmid/21816024&rfr_iscdi=true |